Innovative low toxic drug for the treatment of Parkinson's disease on the basis of monoterpenes

28 january 2019, 18:17
Патенты получены
Стадия разработки (НИР)
Не указано
The drugs currently used in the treatment of Parkinson's disease have limited possibility of prolonged use and a large number of side effects (tachycardia, cardiac arrhythmia, dyskinesia, cognitive impairment, loss of appetite, hallucinations, paranoia, etc.). Novosibirsk research institute scientists synthesized a carbocyclic compound with high anti-parkinsonian activity, which was proven in experimental models, and is not inferior in effectiveness to levodopa. The research allowed obtaining the information on the mechanism of action of the anti-parkinsonic agent, which indicate that the compound is an agonist of dopaminergic and antagonist of M- cholinergic system. It is shown that a new compound when administered orally, virtually eliminates motor and emotional distress caused by the development of the parkinsonian syndrome. Unlike levodopa, the compound is effective in treating symptomatic Parkinson induced by intake of neuroleptics. The compound is low in toxicity; its LD50 is 4250 mg/kg, with effective dose of 10-20 mg/kg. The new compound can be synthesized from common natural compounds monoterpenes - verbenone or α- pinene, a turpentine main component, using available reagents and techniques.
16 раз нам позвонили с откликами по этому предложению. Звоните и вы, +7 383 233-37-03.

Innovative aspects

На основе нового соединения будет разработан лекарственный препарат для лечения болезни Паркинсона с принципиально новым механизмом действия (совмещает свойства агониста дофамина и холинолитика).